Home Stocks Bio-Path Holdings, Inc. Stock listing
OTC:BPTH Bio-Path Holdings, Inc. Stock Follow Bio-Path Holdings, Inc. into a list and get an email when it puts out news.
Ticker OTC:BPTH
Asset type Stock
Sector Health care
Industry Biotechnology
Exchange OTC
Currency USD Bio-Path Holdings, Inc. on 6ix
Calls 18 calls with a replay · 18 with a transcript · latest Nov 15, 2024
Decks 11 decks · latest May 2022 On this page Valuation balance Mar 31, 2026
Enterprise value No market cap
P/E No market cap
EV/sales No market cap
EV/EBITDA No market cap
Price/book No market cap
Gross margin No revenue
Operating margin No revenue
Net margin No revenue
Debt to equity Negative equity
Beta vs S&P 500 0.50 Forecasts 1 buy · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
Price target 2.00 USD · Analysts' mean
EPS, year to Dec 2025 -1.59 · 1 analyst Team and board Officers Officer Role Vikram Grover CEO | Board Chairman Wendy Charles Chief Scientific Officer and Chief Ethics & Compliance Officer
Board Director Role Wendy Charles Chief Scientific Officer and Chief Ethics & Compliance Officer
Events Calls Call When Status Bio-Path Holdings (OTC:BPTH) Q3 2024 Earnings Call Fri, Nov 15, 2024 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q2 2024 Earnings Call Thu, Aug 15, 2024 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q1 2024 Earnings Call Wed, May 15, 2024 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q4 2023 Earnings Call Fri, Mar 08, 2024 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q3 2023 Earnings Call Wed, Nov 15, 2023 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q2 2023 Earnings Call Tue, Aug 15, 2023 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q1 2023 Earnings Call Fri, May 12, 2023 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q4 2022 Earnings Call Fri, Mar 31, 2023 · 8:00 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q3 2022 Earnings Call Tue, Nov 15, 2022 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q2 2022 Earnings Call Tue, Aug 16, 2022 · 8:30 AM ET Replay
All 18 calls Call When Status Bio-Path Holdings (OTC:BPTH) Q1 2022 Earnings Call Tue, May 17, 2022 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q4 2021 Earnings Call Fri, Mar 11, 2022 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q2 2021 Earnings Call Fri, Aug 13, 2021 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q1 2021 Earnings Call Fri, May 14, 2021 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q4 2020 Earnings Call Wed, Mar 10, 2021 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q3 2020 Earnings Call Fri, Nov 13, 2020 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q2 2020 Earnings Call Fri, Aug 14, 2020 · 8:30 AM ET Replay Bio-Path Holdings (OTC:BPTH) Q1 2020 Earnings Call Fri, May 15, 2020 · 8:30 AM ET Replay
Results days Quarter Results Q2 2025 Aug 14, 2025 · After close Q1 2025 May 15, 2025 · After close Q4 2024 Mar 6, 2025 · Before open Q3 2024 Nov 14, 2024 · After close Q2 2024 Aug 14, 2024 · After close Q1 2024 May 14, 2024 · After close Q4 2023 Mar 7, 2024 · After close Q3 2023 Nov 14, 2023 · After close Q2 2023 Aug 14, 2023 · After close Q1 2023 May 11, 2023 · After close
All 19 quarters Quarter Results Q4 2022 Mar 31, 2023 · Before open Q3 2022 Nov 14, 2022 · After close Q2 2022 Aug 15, 2022 · After close Q1 2022 May 16, 2022 · After close Q4 2021 Mar 10, 2022 · After close Q3 2021 Nov 10, 2021 · After close Q2 2021 Aug 12, 2021 · After close Q1 2021 May 13, 2021 · After close Quarter to Dec 31, 2020 Mar 9, 2021 · After close
Open Events
Financials Annual, in USD
Income statement Line FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 Revenue 0 0 0 0 0 0 0 37.0K 13.0K 0 Cost of revenue 178.0K 178.0K 161.0K 151.0K 230.0K 426.0K 8.59M 8.28M 201.8K Gross profit -178.0K -178.0K -161.0K -151.0K -230.0K -426.0K 37.0K 13.0K -201.8K Research and development 7.29M 11.6M 9.16M 5.91M 6.58M 4.58M 4.60M 5.48M 5.47M 3.02M Selling, general and administrative 4.70M 4.11M 4.74M 4.53M 4.33M 4.11M 3.38M 3.52M 3.01M 2.46M Operating income -12.0M -15.8M -13.9M -10.4M -10.9M -8.69M -8.59M -8.97M -8.47M -5.48M Depreciation and amortization 159.0K 178.0K 178.0K 161.0K 151.0K 230.0K 426.0K 411.0K 204.0K 201.8K EBITDA -11.8M -15.7M -13.7M -10.3M -10.8M -8.46M -8.16M -8.55M -8.27M -5.28M Interest expense 33.0K 3.00K 0 0 0 0 0 0 Income before tax -9.89M -16.1M -13.9M -10.4M -10.9M -8.60M -8.58M -7.02M -6.75M -5.47M Income tax -33.0K -3.00K -26.0K -94.0K -608.0K -1.94M -1.73M 0 Net income -9.89M -16.1M -13.8M -10.4M -10.9M -8.51M -8.58M -7.02M -6.75M -5.47M Earnings per share, basic -1.72 -33.64 -38.03 -31.04 -56.44 -64.02 -14.38 -13.93 -14.56 -12.18
Balance sheet Line FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 Cash and equivalents 1.17M 1.05M 10.4M 23.8M 13.8M 20.4M 1.00M 5.96M 9.38M 8.85M Short-term investments 0 0 0 Receivables 0 -3.59K -523 0 775.2K Inventory 632 3.59K 523 1.27K 776 0 0 559.5K Current assets 3.78M 3.04M 15.6M 26.1M 16.0M 22.0M 1.93M 7.43M 10.7M 9.59M Property, plant and equipment 428.0K 231.0K 303.0K 406.0K 654.0K 614.0K 72.0K Goodwill 0 0 0 Total assets 3.88M 3.22M 16.0M 26.6M 16.5M 22.7M 2.33M 8.86M 12.2M 10.8M Accounts payable 1.27M 457.0K 667.0K 106.0K 100.0K 486.0K 813.0K 52.0K 69.0K 54.6K Current liabilities 3.29M 1.91M 1.68M 958.0K 1.17M 1.24M 1.12M 791.0K 1.05M 937.4K Long-term debt 0 0 0 Total debt 113.0K 221.0K 235.0K 330.0K 415.0K Total liabilities 3.73M 2.78M 1.80M 1.11M 1.41M 1.57M 1.12M 791.0K 3.96M 937.4K Shareholders' equity 154.0K 441.0K 14.2M 25.5M 15.1M 21.1M 1.22M 8.07M 8.24M 9.82M Shares outstanding 5.77M 478.0K 363.8K 336.3K 192.3K 132.8K 597.0K 504.0K 463.5K 448.8K
Cash flow Line FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 Cash from operations -10.6M -11.5M -15.1M -9.92M -11.0M -8.36M -6.12M -7.96M -8.15M -5.00M Capital spending 0 0 -21.0K -70.0K -70.0K -70.0K -17.0K -538.0K -338.0K -338.0K Free cash flow -10.6M -11.5M -15.1M -9.99M -11.0M -8.36M -6.14M -8.49M -8.49M -5.00M Cash from investing -70.0K -70.0K -70.0K -17.0K -538.0K -338.0K -338.0K Cash from financing 10.7M 2.20M 1.73M 20.0M 4.29M 27.8M 1.18M 5.08M 9.01M 9.01M Dividends paid 0 0 0 Share buybacks 4.29M 27.8M 1.18M 5.08M 9.01M 0 Change in cash 121.0K -9.33M -13.4M 10.0M -6.67M 19.4M -4.96M -3.41M 521.0K -5.00M
Open Financials
Cap table Built by 6ix from Bio-Path Holdings, Inc.’s releases · as of May 20, 2026
Common shares 50,297,451
Fully diluted 50,297,451 Fully diluted Line Shares As of Common shares 50,297,451 May 20, 2026
Share count over time Count Shares May 20, 2026 50,297,451
Open Cap table
People 6ix reads each seat by machine from the page it links to, and can misread one.
Person Seat Mark P ColonneseOther companies:
Vaxart, Inc. (Chief Financial Officer · Nov 2, 2015 – Apr 3, 2017 · Past); Precipio, Inc. (Chief Financial Officer · Sep 12, 2012 – Feb 18, 2014 · Past) ; Atherogenics Inc (VP Commercial Operations & CFO · Feb 21, 2006 – Dec 31, 2008 · Past) Director · Jul 13, 2017 – Mar 28, 2019 · Past Gillian C Ivers-ReadOther companies:
Clovis Oncology Inc (See Remarks · Nov 15, 2011 – Nov 1, 2022 · Past); Pharmion Corp (EVP, Development Operations · Dec 31, 2005 – Mar 7, 2008 · Past) Director · Sep 10, 2008 – Apr 25, 2014 · Past Aline Sherwood Director · Mar 31, 2022 – Jul 30, 2024 · Past Amy Sing Director · Nov 3, 2014 – Mar 23, 2017 · Past Douglas P Morris Director · Sep 10, 2008 – Jul 30, 2024 · Past Heath Cleaver Director · Feb 11, 2014 – Jul 30, 2024 · Past Michael J Garrison Director · Oct 1, 2012 – Mar 23, 2017 · Past Paul Aubert Director · Feb 1, 2018 – Jul 30, 2024 · Past Peter Henry Nielsen President, CEO & CFO, Director · Mar 28, 2019 – Jul 30, 2024 · Past Tamaro Martina Molsbergen Director · Oct 11, 2019 – Mar 31, 2021 · Past
All 14 people Person Seat Thomas E Garrison Director · Sep 10, 2008 – Dec 2, 2009 · Past Ulrich W Mueller COO & Secretary · Mar 26, 2014 – May 1, 2017 · Past Vikram Grover CEO | Board Chairman · Since at least Nov 5, 2026 Wendy Charles Chief Scientific Officer and Chief Ethics & Compliance Officer · Since at least Nov 4, 2026
Open People
Log in to ask 6ix AI your own questions about Bio-Path Holdings, Inc.